➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Express Scripts
Medtronic
Merck
AstraZeneca

Last Updated: June 25, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Poloxamer 407


Email this page to a colleague

« Back to Dashboard

What is the drug development status for Poloxamer 407?

Poloxamer 407 is an investigational drug.

There have been 4 clinical trials for Poloxamer 407. The most recent clinical trial was a Phase 2 trial, which was initiated on July 20th 2019.

The most common disease conditions in clinical trials are Mucositis, Periodontitis, and Stomatitis. The leading clinical trial sponsors are Greater New York Academy of Prosthodontics, American College of Prosthodontists Education Foundation, and Medical University of South Carolina.

There are three hundred and twenty US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Poloxamer 407
TitleSponsorPhase
Nitazoxanide as a New Local Adjunctive to Nonsurgical Treatment of Moderate PeriodontitisMaha TalaabPhase 2
Use of Topical Subgingival Application of Simvastatin Gel in the Treatment of Peri-Implant MucositisAmerican College of Prosthodontists Education FoundationPhase 2
Use of Topical Subgingival Application of Simvastatin Gel in the Treatment of Peri-Implant MucositisGreater New York Academy of ProsthodonticsPhase 2

See all Poloxamer 407 clinical trials

Clinical Trial Summary for Poloxamer 407

Top disease conditions for Poloxamer 407
Top clinical trial sponsors for Poloxamer 407

See all Poloxamer 407 clinical trials

US Patents for Poloxamer 407

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Poloxamer 407   Get Started Free Aromatase inhibitor-releasing intravaginal device University of Saskatchewan (Saskatoon, CA)   Get Started Free
Poloxamer 407   Get Started Free Poloxamer-based pharmaceutical compositions for treating wounds Professional Compounding Centers of America (Houston, TX)   Get Started Free
Poloxamer 407   Get Started Free Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III Frequency Therapeutics, Inc. (Woburn, MA)   Get Started Free
Poloxamer 407   Get Started Free Orally disintegrating dosage form for administration of avanafil, and associated methods of manufacture and use Vivus, Inc. (Campbell, CA)   Get Started Free
Poloxamer 407   Get Started Free Compositions for an orally active 1,2,4-oxadiazole for the treatment of disease PTC Therapeutics, Inc. (South Plainfield, NJ)   Get Started Free
Poloxamer 407   Get Started Free Bioadhesive compositions for epithelial drug delivery TRILOGIC PHARMA LLC (Tallassee, AL)   Get Started Free
Poloxamer 407   Get Started Free Nanoparticulate compositions and formulations of piperazine compounds REXAHN PHARMACEUTICALS, INC. (Rockville, MD)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Poloxamer 407

Drugname Country Document Number Estimated Expiration Related US Patent
Poloxamer 407 Brazil BR112015026298 2033-04-19   Get Started Free
Poloxamer 407 World Intellectual Property Organization (WIPO) WO2014169395 2033-04-19   Get Started Free
Poloxamer 407 World Intellectual Property Organization (WIPO) WO2015134822 2034-03-05   Get Started Free
Poloxamer 407 Australia AU2015258836 2034-05-16   Get Started Free
Poloxamer 407 Canada CA2949094 2034-05-16   Get Started Free
Poloxamer 407 European Patent Office EP3142640 2034-05-16   Get Started Free
Poloxamer 407 Mexico MX2016014771 2034-05-16   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Merck
McKinsey
Johnson and Johnson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.